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ation, since the corrected P value was not significant. In 
contrast to the decreased frequency of DR52 found in 
English patients with primary antiphospholipid syndrome 
(6), we found a higher frequency of this antigen in our 
patients. Another difference between English and Mexican 
patients is that 92% of the English patients were positive for 
the supertypic antigen HLA-DRS3, whereas in Mexicans the 
frequency of this antigen was similar in patients and con- 
trols. Comparable findings were noted with the HLA-DR4 
antigen, which had a frequency of 76.9% in English patients 
whereas it was found in only 35% of our Mexican patients 
and 42% of Mexican controls (results not shown). Regarding 
the HLA-DQ region, Arnett et a1 (4) reported that HLA- 
DQ7 is associated with the presence of lupus anticoagulant, 
a related aPL, in black and white SLE patients in the US. 
We found no association with HLA-DQ7 in our primary 
antiphospholipid syndrome patients, all of whom had aPL, 
but found that all DRB1*1101 or DRB1*1201 positive pa- 
tients in whom DQ variants were detected were also 
DQB1*0301 positive. In Italian SLE patients, an association 
between anticardiolipin antibodies and HLA-DR7 was 
found (5).  We did not identify such an association in our 
primary antiphospholipid syndrome patients, although we 
did find it in our Mexican SLE patients with secondary 
antiphospholipid syndrome (Vargas-Alarcon G et al: unpub- 
lished results). This difference between patients with the 
primary and those with the secondary antiphospholipid 
syndrome supports the notion that the primary antiphospho- 
lipid syndrome is a distinct entity and not merely a phase in 
the course of SLE. 
Two of our 6 DR5 negative primary antiphospholipid 
syndrome patients had DR8 and 2 had DR3. The DR5 allele 
has the coded sequence of the DRBl region with marked 
homology with DR8 and DR3 alleles, which is in accord with 
the notion that all 3 alleles belong to the DR52 family. The 
DR3 and DR5 alleles share amino acids 9-13 of the first 
hypervariable region from the DRBl gene (Glu, Tyr, Ser, 
Thr, Ser), whereas the DR8 allele differs only at position 
number 13 (10,ll). This sequence could be crucial in the 
antigen recognition that leads to the production of aPL, since 
it is located on the floor of the antigen-recognition site of the 
MHC molecule (12). The finding that 19 of 21 Mexican 
patients with primary antiphospholipid syndrome had alleles 
belonging to the DR52 family, while a similar proportion of 
English patients had alleles belonging to the DR53 family, 
suggests that they result from different point mutations. It 
also suggests that the development of aPL in primary anti- 
phospholipid syndrome may be antigen driven, whereas in 
SLE these autoantibodies may be genetically determined, 
since, in at least 2 different ethnic groups, they were asso- 
ciated with HLA-DR7. 
Our findings indicate an association of DR5 
(DRBl* 1201) with susceptibility to primary antiphospholipid 
syndrome in Mexicans. The relevant gene appears to be 
located near the DRBl gene and to belong to the DR52 
family, whose related alleles share a sequence that could be 
relevant to the antigen recognition site. Additional sequence 
analysis of the HLA-DQ alleles could help define their role 
in the primary antiphospholipid syndrome in Mexican pa- 
tients. 
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Cytarabine therapy for refractory cutaneous lupus 
Treatments for cutaneous lupus include antimalari- 
als, topical and systemic corticosteroids, azathioprine, 
methotrexate and cyclophosphamide, and occasionally, dap- 
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Figure 1. A, Patient 1 before cytarabine therapy. B,  Patient 1 during cytarabine therapy. C, Patient 2 before cytarabine therapy. D, Patient 2 
during cytarabine therapy. E, Patient 3 before cytarabine therapy. F, Patient 3 during cytarabine therapy. 
sone and retinoids (1). In some patients, these medications 
have little effect, while in others, intolerable side effects may 
develop, indicating a need for additional therapeutic inter- 
ventions. Cytarabine (cytosine arabinoside) is a cytidine 
analog with potent immunosuppressive properties (2) that 
has recently been used to treat rheumatoid arthritis (RA) (3). 
Furthermore, cytarabine can increase DNA methylation 
(4,5), and diminished T cell DNA methylation has been 
implicated in the pathogenesis of systemic lupus erythema- 
tosus (SLE) (6,7). These considerations prompted us to 
investigate the efficacy of cytarabine in patients with refrac- 
tory cutaneous lupus. 
We treated 3 female patients, using a protocol previ- 
ously shown to be immunosuppressive in humans (8). Writ- 
ten consent was obtained from all patients. None of the 
patients had significant hematologic abnormalities or impair- 
ment of renal function, none were receiving other DNA syn- 
thesis inhibitors, and all were using effective contraception. 
Cytarabine was administered subcutaneously at 2 
m a g  for 5 consecutive days, together with ondansetron 
orally 8 mg 3 times a day. This was repeated every fourth 
week for a total of 3 courses. Clinical assessment (Systemic 
Lupus Activity Measure) (9) and routine laboratory moni- 
toring were performed weekly for the first cycle, then every 
other week for a total of 12 weeks. 
Patient 1 is a 23-year-old woman who has had SLE 
for 17 years, manifested by a rash involving the face, hands, 
and upper trunk, photosensitivity, alopecia, oralhasal ulcer- 
ations, arthritis, serositis, fatigue, Raynaud’s phenomenon, 
leukopenia, hypocomplementemia, positive antinuclear an- 
tibodies (ANA), and positive autoantibodies to double- 
stranded DNA and Sm. She had previously been treated 
with hydroxychloroquine, chloroquine, quinacrine, pred- 
nisone, azathioprine, levamisole, methotrexate, cyclo- 
phosphamide, and nitrogen mustard. A combination of in- 
travenous cyclophosphamide, prednisone (30 mglday), and 
antimalarials resulted in mild improvement, but was compli- 
cated by retinal pigmentation, cataracts, and avascular ne- 
crosis. The other medications were either ineffective or 
poorly tolerated. 
CONCISE COMMUNICATIONS 1343 
Cytarabine was administered at 2 mg/kg/day on 
weeks 1,5,  and 9. During the second week of each cycle, her 
rash began to clear, with maximum improvement during the 
third week (Figures 1A and B), and began to relapse during 
the fourth week. Improvement in fatigue, Raynaud’s phe- 
nomenon, dyspnea, headache, and cortical dysfunction were 
also reported. Her C3 level normalized, and her C4 level 
rose from undetectable to borderline low. Therapy was 
accompanied by asymptomatic mild thrombocytopenia 
(147,000/mm3) occumng during the second week. A mild 
leukopenia (3, 1W/mm3) was observed on one occasion. 
Because the cutaneous improvement was not sustained, her 
prednisone dose was increased from 30 to 40 mg/day during 
the third course; however, this did not prolong the response. 
Patient 2 is a 44-year-old woman who has had lupus 
for 15 years, manifested by photosensitivity, alopecia, dis- 
coid and ulcerative scalp lesions requiring skin grafts in 
1988, arthritis, oral ulcerations, fatigue, serum positive for 
ANA, and autoantibodies to Ro. Treatment with prednisone, 
quinacrine, chloroquine, azathioprine, and hydroxychloro- 
quine was previously ineffective. Cytarabine was adminis- 
tered as with Patient 1. Mild nausea and 1 episode of emesis 
accompanied the first course. Her scalp lesions began to 
improve by the second week, and improved slowly but 
continuously over the second course of therapy (Figures 1C 
and D). Improvement in arthritis was also noted. The dose of 
cytarabine was increased to 3 mg/kg/day for the third cycle 
in an attempt to improve the clinical response. This resulted 
in several episodes of emesis and a diffuse pruritic rash due 
either to the ondansetron or cytarabine, but neither throm- 
bocytopenia nor leukopenia were present. No further in- 
crease in efficacy was observed at this dose, and the pa- 
tient’s scalp disease relapsed 4 weeks after the last cycle. 
Patient 3 is a 35-year-old woman who has had sub- 
acute cutaneous lupus for 14 years, manifested by a non- 
scarring photosensitive rash, arthritis, oral and nasal ulcers, 
serositis, Raynaud’s phenomenon, fever, fatigue, serum 
positive for ANA, and autoantibodies to Ro. Treatment with 
prednisone, azathioprine, quinacrine, hydroxychloroquine, 
dapsone, and sulfapyridine was either ineffective or poorly 
tolerated. Cytarabine was administered as above. Again, 
dramatic clearing of the skin lesions was observed during the 
second and third week of therapy (Figures 1E and F), with a 
tendency to relapse during the fourth week. Because of the 
transient improvement, her dose was increased to 3 mg/kg/ 
day during the third cycle of therapy. This was complicated 
by thrombocytopenia (24,000/mm3) and menorrhagia. The 
platelet count normalized within 1 week, but the increased 
dose did not result in prolonged skin improvement. 
In these 3 cases, cytarabine caused a significant 
response in otherwise refractory cutaneous lupus. The im- 
provement was rapid, but relapsed during the fourth week in 
2 cases. Other disease manifestations also appeared to 
improve, suggesting that cytarabine might be effective for 
other SLE manifestations. Attempts to prolong the response 
with higher doses resulted in increased toxicity, with no 
apparent additional benefit. More frequent dosing, such as 
every 3 weeks, or possibly a lower dose given daily, would 
likely produce a more consistent response. 
The major toxicities encountered were nausea, 
thrombocytopenia, and 1 allergic reaction. Thrombocytope- 
nia was potentially the most serious complication, but this 
resolved rapidly, as observed earlier (3). Thrombocytopenia 
was most severe at 3 mg/kg of cytarabine. Since lower doses 
were equally effective, there should be no need to use higher 
doses in future studies. Leukopenia was also observed, but 
was mild and uncomplicated. The allergic reaction was a 
diffuse pruritic rash, which may represent an idiosyncratic 
reaction to 1 of the medications. 
The clinical benefit observed may be due to cytara- 
bine’s known immunosuppressive effects. However, it is 
noteworthy that azathioprine and prednisone were not effec- 
tive in these patients. This raises the possibility that addi- 
tional properties unique to cytarabine, such as DNA hyper- 
methylation, might contribute to its apparent increased 
efficacy. It would thus be important to serially measure T 
cell deoxymethylcytosine content. Unfortunately, the large 
amount of blood required for each determination (7) has 
precluded these studies. Nonetheless, the results support the 
hypothesis that immunosuppressives that hypermethylate 
DNA might be more effective than other immunosuppres- 
sives in the treatment of cutaneous lupus. 
In summary, cytarabine appears to be an effective 
treatment for these 3 patients with otherwise refractory 
cutaneous lupus. Further studies appear to be justified. 
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